Clinical and molecular heterogeneity of microsatellite instability-high colorectal cancer in older adults
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.123709 ↗Abstract
BACKGROUND Although universal screening for Lynch syndrome is gaining increased support, the clinical utility of microsatellite instability (MSI) testing in older patients remains controversial. Consequently, MSI-high (MSI-H) colorectal cancer (CRC) in older adults is generally considered a sporadic disease driven by aging, and the actual molecular heterogeneity in this population remains underappreciated. AIM To define age-specific clinicopathological MSI-H CRC features in an aging East Asian population and challenge the assumption of uniformly sporadic older MSI-H CRC. METHODS Data of 573 consecutive patients who underwent surgical resection for primary CRC between 2013 and 2025 were retrospectively analyzed. MSI status was determined using five mononucleotide markers or mismatch repair immunohistochemistry. The patients were stratified into older (≥ 71 years; n = 289) and younger (≤ 70 years; n = 284) groups. RESULTS The prevalence of MSI-H CRC was comparable across groups: 7.4% in the older group and 7.6% in the younger group (P = 1.0). Although the older group had significantly more BRAF mutations (P < 0.001), the molecular landscape was heterogeneous. Of the older MSI-H patients, 28.6% (6/21) exhibited non-sporadic, atypical profiles, including four BRAF wild-type cases with MLH1 deficiency and two with MSH2 or MSH6 deficiencies. A 72-year-old patient with an MSH6 mutation was definitively diagnosed with Lynch syndrome, a condition that would have remained undetected under the conventional age-restricted screening guidelines. CONCLUSION Although limited by a small sample size, nearly 30% of older patients with MSI-H CRC in our cohort exhibit atypical molecular profiles, suggesting that older age does not uniformly imply sporadic disease. Relying strictly on age to triage patients carries a risk of missing Lynch syndrome. Further larger studies are needed to confirm whether reflex MLH1 promoter methylation analysis should be performed regardless of age to optimize precision medicine.
EUVIMED